GLO Dutch Bidco / Mallinckrodt Netherlands and Mallinckrodt Nuclear Medicine merger inquiry
The CMA is investigating the completed acquisition by GLO Dutch Bidco of Mallinckrodt Netherlands Holdings BV and Mallinckrodt Nuclear Medicine LLC.
|Phase 1 Date||Action|
|4 July 2017||Deadline for phase 1 decision (*)|
|8 May 2017||Launch of merger inquiry|
|24 March 2017||Initial enforcement order|
(*) This date is the current statutory deadline by when the decision will be announced. If any change occurs, the information is refreshed as soon as practicable. However, the CMA cannot guarantee that the decision will be announced on or before this current deadline, as the deadline of a given case may change during the merger assessment process due to different reasons.
Launch of merger inquiry
8 May 2017: The CMA announced the launch of its merger inquiry by notice to the parties.
Initial enforcement order
31 March 2017: On 24 March 2017, the CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on GLO BidCo S.ả r.l., IBA Pharma SA, GLO Dutch Bidco, B.V. and Mallinckrodt Netherlands Holdings BV, in relation to the completed acquisition GLO Dutch Bidco B.V. of Mallinckrodt Netherlands Holdings B.V. and Mallinckrodt Nuclear Medicine LLC.
- Derogation 11 May 2017 (12.5.17)
- Derogation 28 March 2017 (31.3.17)
- Derogation 30 March 2017 (31.3.17)
Please send written representations about any competition or public interest to:
Competition and Markets Authority
Published: 30 March 2017
Opened: 30 March 2017
- Derogation published.
- Launch of CMA merger inquiry
- Variation order published.
- Initial enforcement order and derogations published.
- First published.